Key result
Guideline-directed medical therapy for heart failure is often initiated late, under-titrated, or discontinued in routine practice, diluting the benefits seen in clinical trials.
Answers are grounded in this paper and cite their sources.
Highlights the urgent need for rapid initiation and titration of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction to reduce mortality and hospitalizations.
Heart failure (HF) represents one of the most pressing health challenges globally, affecting more than 64 million people worldwide.Despite therapeutic progress, HF remains a leading cause of hospitalization and mortality, particularly in patients with reduced ejection fraction (HFrEF), with annual costs, including hospitalizations, pharmacotherapy, and productivity losses, measured in the hundreds of billions of dollars [1,2]. Readmissions remain common: roughly one in four patients is rehospitalized within 30 days in many healthcare systems, and one in two within 6 months, reflecting not only the complexity of patients with HF but also the challenges of post-discharge care [3].Despite decades of advances, 5-year mortality in HF approximates that of many cancers, thereby underscoring the urgency for better care delivery [2,3].Currently, multiple therapies unequivocally reduce death and hospitalization in HFrEF.Yet, these therapies are initiated late, under-titrated, or discontinued in routine practice, hence diluting the benefits seen in trials [4,5].
No takes yet. Share an insight, caveat, or question.
Karam et al. (2026) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Guideline-directed medical therapy (GDMT) was evaluated. Guideline-directed medical therapy for heart failure is often initiated late, under-titrated, or discontinued in routine practice, diluting the benefits seen in clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: